TRT for Longevity: The Healthspan Argument

The healthspan problem TRT addresses

Healthspan is the years you spend functional, strong, mobile, sharp, sexually active, independent. The biggest threats to healthspan after 50 are sarcopenia (muscle loss), osteopenia (bone loss), insulin resistance, cognitive decline, and cardiovascular disease. Testosterone is upstream of every one of these systems in men.

By age 60, the average untrained man has lost ~15% of peak muscle mass and ~10% of peak bone density, while testosterone has dropped 30-40% from its 30-year-old peak. The decline curves are coupled. Restoring testosterone to a healthy young-adult range slows or partially reverses each of them.

What the TRAVERSE trial actually showed

TRAVERSE, published in NEJM in 2023 and updated through 2024, was the largest cardiovascular safety trial of TRT ever run. 5,200 men with low testosterone and pre-existing cardiovascular disease, randomized to TRT or placebo, followed for 33 months. Results:

• No increase in major adverse cardiovascular events (MACE) on TRT
• No increase in cardiovascular mortality
• No increase in prostate cancer
• Modest increases in atrial fibrillation and pulmonary embolism (small absolute risks, monitorable)
• Improvements in fatigue, sexual function, and bone density

The verdict: in monitored TRT for men with documented hypogonadism, the cardiovascular boogeyman doesn't exist. This was the trial that finally moved TRT from "controversial" to "cardiovascular-safe with appropriate use."

Muscle: the biggest healthspan lever

Lean mass and grip strength are stronger predictors of mortality after 60 than blood pressure or cholesterol. TRT directly preserves and rebuilds both. Studies of men on monitored TRT show:

• 5-8% increase in lean mass in the first year
• 10-15% increase in grip strength
• 3-6% reduction in fat mass, especially visceral fat
• Effects largest in men who pair TRT with resistance training

Without TRT, men over 50 who train hard can hold the line on muscle loss but rarely add. With optimized testosterone, building muscle is genuinely possible into the 70s.

Bone density and fracture risk

Testosterone is anabolic to bone, partly directly and partly via aromatization to estradiol (which is the primary regulator of male bone density). Men with low testosterone have measurably lower bone density and ~50% higher hip fracture risk in their 70s. TRT restores both.

Hip fracture in older adults is functionally a terminal event, 25-30% one-year mortality, with the majority of survivors never returning to prior independence. Preventing it is one of the highest-leverage interventions in late life. TRT is one of the only pharmaceutical tools that improves bone density meaningfully in men.

Metabolic and cardiovascular markers improve

The metabolic story is consistent across studies:

• Insulin sensitivity: 25-30% improvement
• HbA1c: 0.5-1.0 point reduction in diabetic men
• Visceral fat: 10-20% reduction over 12 months
• Triglycerides: down 10-20%
• Inflammation (hs-CRP): down 15-30%

The metabolic improvements appear to drive most of TRT's longevity signal in observational data, not the testosterone itself, but the downstream changes it produces.

What "longevity TRT" looks like in practice

Longevity-focused TRT differs from purely symptom-focused TRT in a few ways:

• Conservative dosing targeting upper-normal total T (700-1000 ng/dL), not supraphysiologic
• Weekly or twice-weekly injections for stable levels (vs. older biweekly protocols that produce roller-coaster levels)
• Estradiol management kept in the optimal 20-40 pg/mL range
• Hematocrit monitoring every 6 months to catch elevation early
• PSA monitoring annually after age 40
• Paired with resistance training, adequate protein, and 7+ hours of sleep

This protocol gets the muscle, bone, metabolic, and cognitive benefits with very low risk of side effects.

Who is and isn't a candidate

TRT for longevity makes sense for men with:

• Documented low or low-normal testosterone (typically <500 ng/dL with symptoms, or <350 ng/dL regardless)
• Symptoms aligned with low T (fatigue, low libido, poor recovery, etc.)
• No active prostate cancer, untreated severe sleep apnea, or untreated polycythemia
• Willingness to monitor labs every 6-12 months

It's not appropriate for healthy men with normal levels seeking "supraphysiologic" performance enhancement, that's a different protocol with different risks.

The bottom line

TRT used as a longevity tool, conservatively dosed, lab-driven, paired with training, addresses muscle, bone, metabolic, and cognitive decline simultaneously. Post-TRAVERSE, the cardiovascular concerns that historically held the field back have been resolved. For men with documented low testosterone, the question is no longer whether TRT is safe; it's whether the protocol is dialed in.